Workflow Control Becomes the Moat, AI Defends Margins, and Trusted Identity Owns Exchange

By DripPublished

The gist

This week HealthTech shifted toward infrastructure that controls workflow, reimbursement, identity, and care pathways—where the margin and moat are moving.

This week’s developments

Workflow Infrastructure Becomes the Value-Based Care Moat

Basalt Health raised $20 million to push post-acute transition software from point automation into workflow infrastructure, automating referral intake, clinical review, benefits verification, prior authorization, and discharge planning; Lifepoint said the platform cut median processing time 86%, from 8.5 minutes to 1.2. The raise matters because value-based care is already paying for orchestration, with MSSP ACOs generating about $2.5 billion in net Medicare savings and $4.1 billion in performance payments, while kidney-care programs reported $3.6 million in plan savings, 30% lower hospitalizations, 50% higher home dialysis, and a 43% lower cost trend. Competitive advantage is shifting to vendors that can control workflow, integrate into enterprise systems, and prove outcomes.

Where will workflow control create the strongest value-based care moat?

If you operate in this industry

  • Workflow control is becoming the moat in value-based care.
  • If you can't own intake-to-discharge workflows, you'll get commoditized by platforms that can prove faster, cheaper transitions.

Sources

If you sell into this industry

  • Buyers now pay for orchestration, not isolated automation.
  • Shift roadmap and GTM toward embedded workflow infrastructure, enterprise integrations, and outcome proof—not standalone point features.

Sources

If you invest in this industry

  • Value-based care is rewarding workflow platforms, not point tools.
  • Favor vendors with system-level workflow control and measurable savings; point solutions without integration depth face multiple compression.

Sources

AI Moves from Copilot to Margin-Defense Infrastructure

XiFin said clinical lab, molecular, and genomics denial rates rose to 11.2% in 2025 from 8.0% in 2024, sharpening the ROI case for AI in reimbursement-heavy workflows. At the same time, vendors pushed deeper into the exact pressure points: dental billing, denial management, lab appeals, staffing relief, risk adjustment, and now voice control inside LigoLab’s LIS. In dental RCM, adoption intent is rising around eligibility checks, claim scrubbing, denial routing, and payment reconciliation, with one survey showing 58% of practices adopting or planning AI and another showing 63% using RCM software, up from 47% in 2021 to 2023.

The market is moving from documentation copilots to workflow control that protects reimbursement and offsets scarce labor. Teladoc added AI vitals capture and documentation, UNC Health and Zivian are scaling AI in clinical workflows, Suki is broadening major-vendor integrations, and Abridge secured a systemwide rollout in Texas. Experian’s finding that 63% of providers have introduced AI but only 15% have fully integrated it shows the real gap is operationalization. The winners will be embedded platforms that measurably reduce denials, replace labor, and accelerate reimbursement.

Where will reimbursement-defense AI create the most defensible value?

If you operate in this industry

  • AI is becoming reimbursement defense, not just workflow sugar.
  • Prioritize AI that cuts denials, speeds appeals, and offsets labor; point tools without measurable margin impact will get squeezed.

Sources

If you sell into this industry

  • Buyers want embedded AI that moves cash, not standalone copilots.
  • Shift roadmap to native denial, billing, and reconciliation workflows; prove ROI in reimbursement-heavy use cases to win enterprise deals.

Sources

If you invest in this industry

  • Value is shifting to platforms that own reimbursement workflows.
  • Favor vendors with embedded distribution and measurable denial reduction; standalone copilots and thin point tools face margin pressure.

Sources

Trusted Identity Becomes the Access Layer for Health Data Exchange

Datavant embedded ID.me’s reusable digital identity verification into its Patient Request Tool, pulling medical-record requests into the workflow and eliminating a separate manual identity check; ID.me says 73% of patients using the integration were already credentialed. The move reinforces a broader shift toward FHIR-based distribution through TEFCA-related connectivity, SMART on FHIR prior authorization, and Bulk FHIR population queries. Strategically, access is moving from staff-mediated exchange to identity-verified APIs, raising the bar for vendors: the moat is no longer just data aggregation or workflow automation, but bundled identity proofing, FHIR tooling, and auditable connectivity that speeds patient access and reduces manual review.

Where will trusted identity capture the most value in FHIR workflows?

If you operate in this industry

  • Identity-verified APIs are replacing manual exchange as the default gate.
  • If your workflow still depends on staff checks, you're exposed; build or buy identity proofing plus FHIR-ready access now.

Sources

If you sell into this industry

  • Bundled identity and FHIR tooling is becoming the new enterprise baseline.
  • Roadmaps need native identity proofing, auditability, and TEFCA/SMART/Bulk FHIR hooks or you'll lose deals to platform bundles.

Sources

  • Who owns trust in financial services? — FinTech Global, September 21, 2026

    Explains how digital identity, auditability, and shared risk signals are becoming core platform requirements.

If you invest in this industry

  • Value is shifting to trusted access layers, not just record aggregation.
  • Favor vendors that own identity plus connectivity; pure workflow or data brokers face margin pressure as access gets API-ized.

Sources

Care Delivery Is Consolidating Around Workflow Control

iRhythm’s planned acquisition of VitalConnect and McKesson/CD&R’s agreed $5.8 billion purchase of Option Care Health show care delivery competition shifting from standalone products to control of the full monitoring and treatment workflow. iRhythm said VitalConnect adds mobile cardiac telemetry, multi-vitals, and hospital monitoring to its ambulatory cardiac platform, extending coverage across ambulatory, inpatient, remote, and hospital-to-home use cases. McKesson and CD&R will split ownership roughly 51%/49%, with closing expected in 1H 2027.

The same week, Harbor Health expanded by acquiring VillageMD clinic locations and Midea finalized its acquisition of Esaote, reinforcing the same pattern across primary care and imaging: buyers are bundling devices, data, and delivery sites into broader operating systems. The strategic implication is clear: reimbursement proof and point solutions are no longer enough on their own. Value is moving toward platform owners with distribution leverage, interoperable data flows, and enough service depth to become the default layer across settings.

Where will workflow control create the next defensible advantage?

If you operate in this industry

  • Workflow control is becoming the moat, not the device itself.
  • Build or buy across settings now; standalone reimbursement wins won’t defend share if rivals own the monitoring-to-treatment workflow.

Sources

If you sell into this industry

Sources

If you invest in this industry

Sources

Stay ahead in HealthTech

Get the weekly HealthTech brief in your inbox — the developments, what they mean by vantage, and what to do next.